FMP
Gamida Cell Ltd.
GMDA
NASDAQ
Inactive Equity
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.
0.0327 USD
-0.0073 (-22.32%)
2023
2022
2021
2020
1.78M
0
0
0
3.48M
440k
431k
357k
-1.69M
-440k
-431k
-357k
70.95M
74.99M
87.17M
62.3M
22.28M
42.69M
50.18M
41.38M
48.66M
19.4M
16.98M
12.17M
4.08M
12.9k
20.01k
8.89k
44.58M
19.4M
16.98M
12.17M
-395k
12.9M
20.01M
8.75M
-72.64M
74.99M
-87.17M
-62.3M
9.65M
-4.38M
-2.63M
-648k
-63M
-79.38M
-89.79M
-72.7M
-1
74.99M
2.63M
3.74M
-63M
-154.37M
-92.42M
-76.45M
-0.57
-2.42
-1.56
-1.75
-0.57
-2.42
-1.56
-1.75
110.05M
63.83M
59.25M
43.73M
110.05M
63.83M
59.25M
43.73M
-70.62M
-74.55M
-86.74M
-60.57M
All figures are in USD.